ResMed (RMD) vs Solventum (SOLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Solventum (SOLV) has outperformed ResMed (RMD) over the past year, gaining 19.0% versus a loss of 19.7%. ResMed is the larger company by market cap ($31.89 billion vs $14.71 billion), about 2.2 times the size. On valuation, Solventum trades at a lower forward P/E (12.0x vs 17.1x for ResMed).
ResMed pays a dividend yielding 1.06%, while Solventum does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 18.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RMD | SOLV |
|---|---|---|
| Share price | $226.73 | $86.41 |
| Market cap | $31.89B | $14.71B |
| 1-day change | +0.33% | +0.62% |
| YTD return | -5.87% | +8.38% |
| 1-year return | -19.70% | +19.01% |
| 5-year return | -11.26% | — |
| P/E ratio (TTM) | 21.74 | 10.58 |
| Forward P/E | 17.14 | 11.95 |
| EPS (TTM) | $10.43 | $8.17 |
| Dividend yield | 1.06% | 0.00% |
| Annual dividend | $2.40 | $0.00 |
| Revenue (latest FY) | $5.65B | $8.32B |
| Revenue growth (YoY) | +9.85% | +0.86% |
| Net income (latest FY) | $1.52B | $1.56B |
| Gross margin | 61.06% | 53.47% |
| Operating margin | 33.37% | 26.20% |
| Net margin | 26.94% | 18.69% |
| 52-week high | $284.05 | $94.16 |
| 52-week low | $180.27 | $62.38 |
| Distance from 52-week high | -20.18% | -8.23% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +10.36% | +9.14% |
| Average volume | 1.34M | 1.02M |
| Shares outstanding | 140.64M | 170.22M |
| Employees | 11,370 | 20,584 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ResMed is about 2.2 times larger than Solventum by market value ($31.89B vs $14.71B).
- SOLV has outperformed RMD by 38.7 percentage points over the past year.
- ResMed trades at a higher earnings multiple (21.7x vs 10.6x trailing P/E).
- ResMed offers a meaningfully higher dividend yield (1.06% vs 0.00%).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 18.7 cents for Solventum.
- ResMed grew revenue faster in its latest fiscal year (+9.85% vs +0.86%).
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
About Solventum
SOLV stock →Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Health Care · Medical/Dental Instruments · 20,584 employees
RMD vs SOLV FAQ
Which is bigger, ResMed or Solventum?
ResMed (RMD) is larger, with a market capitalization of $31.89B compared with $14.71B for Solventum (SOLV).
Which stock has performed better over the past year, RMD or SOLV?
SOLV returned +19.01% over the past 12 months, compared with -19.70% for RMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, RMD or SOLV?
SOLV has the lower trailing P/E at 10.6, versus 21.7 for RMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, ResMed or Solventum?
ResMed pays a dividend yielding 1.06%, while Solventum does not currently pay a regular dividend.
Are ResMed and Solventum in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.